证券代码：301263 证券简称：泰恩康 公告编号：2025-038 本员工持股计划的锁定期已于 2025 年 5 月 6 日届满，具体情况详见公司于 2025 年 5 月 7 日披露于巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 二、本员工持股计划减持情况 本员工持股计划于 2025 年 6 月 4 日至 2025 年 6 月 20 日期间，通过集中竞 价交易方式累计减持公司股票 5,694,348 股，占公司总股本的 1.3383%。 截至本 公告披露日，本员工持股计划所持公司股票已全部减持完毕。 三、其他相关说明 减持期间，公司严格遵守市场交易规则及中国证监会关于信息敏感期不得 买卖股票的规定， 不存在利用内幕信息进行交易的情形。 广东泰恩康医药股份有限公司 关于 2024 年员工持股计划减持完毕的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、本员工持股计划基本情况 广东泰恩康医药股份有限公司（以下简称"公司"）于 2024年 3月 27日召 开第五届董事会第二次会议和第五届监事会第二次会议，于 2024年 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Core Viewpoint - The innovative drug sector in the A-share market has seen significant stock price increases, with several leading companies achieving over 100% growth in 2023, driven by breakthroughs in new drug development [1] Group 1: Company Developments - Shuyou Shen's investigational drug for hemophilia has received breakthrough therapy designation and has submitted a conditional marketing application [1] - Taiankang's innovative drug CKBA ointment has been recognized for its research published in the top immunology journal, Immunity, highlighting its potential in treating vitiligo [1][2] - The research team led by Wang Honglin at Shanghai Jiao Tong University has identified a novel pathogenic mechanism in vitiligo involving sensory neurons and CGRP, which could lead to new treatment strategies [6][7] Group 2: Clinical Trials and Research Findings - The study revealed that blocking the CGRP receptor with Rimegepant significantly inhibits disease progression in vitiligo mouse models and shows promising results in a clinical trial with 57 patients [2][8] - The ongoing Phase II clinical trial for CKBA ointment aims to evaluate its safety and efficacy in non-segmental vitiligo patients, with results expected in July 2023 [11] - The research indicates that CKBA ointment can effectively suppress autoreactive CD8+ T cells, offering a differentiated approach compared to existing treatments [12] Group 3: Market Potential - The global prevalence of vitiligo is estimated at 0.5% to 2%, with approximately 30 million patients in China, indicating a substantial market opportunity for effective treatments [9][12] - The potential market for innovative vitiligo drugs in China is projected to exceed 20 billion yuan, highlighting the demand for targeted therapies [12] - Despite the approval of Ruxolitinib for vitiligo, its market share remains limited, underscoring the need for new therapies to meet patient needs [12]

Group 1 - The hair medical concept sector declined by 0.99%, ranking among the top declines in concept sectors, with stocks like Kanghui Pharmaceutical and *ST Jinbi hitting the limit down [1] - Within the sector, major decliners included Aoyang Health and Tainkang, while stocks that increased included Shuiyang Co., Yisheng Pharmaceutical, and Nengte Technology, with respective increases of 4.13%, 1.81%, and 1.58% [1] - The hair medical concept sector experienced a net outflow of 228 million yuan from main funds, with 14 stocks seeing net outflows, and 6 stocks with outflows exceeding 10 million yuan [2] Group 2 - The top net outflow stocks included Tainkang with a net outflow of 63.36 million yuan, followed by *ST Jinbi and Aoyang Health with outflows of 59.14 million yuan and 57.88 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Xianju Pharmaceutical, Yisheng Pharmaceutical, and Guoyao Modern, with net inflows of 6.84 million yuan, 5.62 million yuan, and 3.33 million yuan respectively [3] - The trading volume for Tainkang was 5.55%, while *ST Jinbi had a turnover rate of 21.44%, indicating significant trading activity in these stocks despite the declines [2]

Group 1: Market Performance - The weight loss drug concept index rose by 1.46%, ranking 7th among concept sectors, with 27 stocks increasing in value [1] - Notable gainers included Zhongsheng Pharmaceutical, which hit the daily limit, and Hanyu Pharmaceutical, Yipinhong, and Tianenkang, with increases of 13.58%, 9.40%, and 9.35% respectively [1] - The sector experienced a net outflow of 600 million yuan in capital, with 23 stocks seeing net inflows, and 6 stocks receiving over 30 million yuan in net inflows [2] Group 2: Capital Flow - Leading the net inflow of capital was Lepu Medical, with a net inflow of 176 million yuan, followed by Hengrui Medicine and Ganli Pharmaceutical with net inflows of 164 million yuan and 117 million yuan respectively [2] - The top three stocks by net inflow ratio were Kexing Pharmaceutical, Lepu Medical, and Ganli Pharmaceutical, with net inflow ratios of 9.86%, 9.24%, and 8.74% respectively [3] Group 3: Stock Performance - The stock performance table indicated that Lepu Medical had a daily increase of 4.10% with a turnover rate of 8.77%, while Hengrui Medicine rose by 1.42% with a turnover rate of 0.75% [3] - Other notable performers included Tianenkang with a 9.35% increase and a turnover rate of 10.42%, and Kexing Pharmaceutical with a 6.40% increase and a turnover rate of 3.35% [4]

Core Insights - The hair medical concept sector has seen a rise of 2.25%, ranking third among concept sectors in terms of growth [1] - Within this sector, 11 stocks increased in value, with notable performers including Aoyang Health, Kanghui Pharmaceutical, and *ST Meigu, which reached their daily limit [1] - The sector experienced a net inflow of 64 million yuan from main funds, with Aoyang Health leading the inflow at 68.73 million yuan [2][3] Sector Performance - The hair medical concept sector's performance is highlighted by the following stocks: - Aoyang Health: increased by 10.12% with a turnover rate of 26.84% and a net inflow of 68.73 million yuan [3] - Taiankang: increased by 9.35% with a turnover rate of 10.42% and a net inflow of 51.69 million yuan [3] - Kanghui Pharmaceutical: increased by 9.99% with a turnover rate of 4.06% and a net inflow of 33.06 million yuan [3] - Huailong Co.: increased by 3.35% with a turnover rate of 11.07% and a net inflow of 14.87 million yuan [3] Fund Flow Analysis - The top stocks by net inflow ratio in the hair medical sector include: - Kanghui Pharmaceutical: net inflow ratio of 36.67% [3] - *ST Meigu: net inflow ratio of 11.74% [4] - Aoyang Health: net inflow ratio of 7.40% [3] - The overall trend indicates a strong interest from main funds in the hair medical sector, with several stocks showing significant inflows [2][3]

Market Overview - A-shares and Hong Kong stocks experienced a decline in the afternoon, with the ChiNext Index and STAR 50 Index dropping over 1% [1] - The Shanghai Composite Index closed down 0.44% at 3384.82 points, while the Shenzhen Component Index fell 0.86% to 10162.18 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 145.16 billion yuan, an increase of nearly 140 billion yuan compared to the previous day [1] Banking Sector Performance - The banking sector showed strength, with Minsheng Bank rising nearly 3% and reaching a peak increase of about 4% during trading [4] - Other banks such as Zhejiang Commercial Bank and Xi'an Bank also saw gains of approximately 2% [4] - Recent announcements of dividend distributions by several banks have led to a more favorable outlook for the sector, with historical data indicating stable performance during the traditional dividend period of June to July [6] Departure Tax Refund Concept - The departure tax refund concept surged, with China National Aviation rising by 30% and several other companies hitting their daily limit [8] - The State Administration of Taxation reported a 116% year-on-year increase in the number of departure tax refunds processed in the first month of the new policy [10] - The potential market space for departure tax refunds is estimated to be nearly 100 billion yuan, which could further stimulate consumption and expand domestic demand [10] Agricultural Sector Activity - The agricultural sector saw significant activity, particularly in seed companies, with Qiu Le Seed Industry rising approximately 12% and Kangnong Seed Industry increasing over 10% [12] - The Ministry of Agriculture has initiated inspections of seed production bases to ensure the safety and quality of agricultural seeds, which is expected to enhance market order and industry standards [14]

Industry Overview - The hair medical sector has shown significant activity recently, with the sector index reaching a new high as of June 10, 2023, driven by active stock performances from companies like Aoyang Health and Kanghui Medical [1] - The hair medical services can be divided into hair transplant services and medical hair care services, with hair transplant services currently dominating the market [1] - The growing trend of beauty economy and self-consumption is leading consumers to invest more time and money in hair health and aesthetics, which is expected to drive continuous growth in the hair medical industry [1] - According to Frost & Sullivan, the market size of hair medical services in China is projected to reach 138.1 billion yuan by 2030, with a CAGR of 22.3% from 2020 to 2030 [1] Market Dynamics - The medical hair care market is expected to grow rapidly due to the high frequency and repurchase characteristics of hair care services, with the "hair transplant and care" integration trend driving this growth [2] - By 2030, the medical hair care services are anticipated to account for 45.3% of the total hair medical services market in China, becoming a significant driver of industry development [2] Key Companies - Zhendong Pharmaceutical (300158): The company's main product, Dafeixin Minoxidil Solution, is the only topical medication approved by both the FDA and NMPA for treating hair loss [2] - Huilong Co., Ltd. (002556): The company offers hair growth and hair loss treatment products, including Zhi Zhi Hair Growth Tablets and Compound Ginseng Phenol Solution, which have national drug approval [2] - Kanghui Pharmaceutical (603139): The company has several drugs listed in the national medical insurance directory, including hair loss treatment tablets [3] - Aoyang Health: The company's subsidiary, Weien Medical Beauty, includes hair transplant services [4] - Tainkang (301263): The company is applying for a one-time import of raw materials for Baricitinib, which is under research for hair growth indications [4] - Kangyuan Pharmaceutical: The new hair loss treatment drug Minoxidil Tincture has completed registration verification and GMP compliance checks [4] - Langzi Co., Ltd. (002612): The company has medical beauty institutions that offer hair transplant-related services [5] - Huabang Health (002004): The company has a hair transplant center under Maan Skin, utilizing MN-FUE hair transplant technology for patient treatment [6]

Group 1 - The hair medical concept sector increased by 3.82%, ranking fifth among concept sectors, with 18 stocks rising, including Aoyang Health which hit the daily limit, and Tainkang, Jiuzhitang, and Kangyuan Pharmaceutical showing significant gains of 13.80%, 5.79%, and 5.73% respectively [1][2] - The hair medical concept sector attracted a net inflow of 132 million yuan from main funds today, with 10 stocks receiving net inflows, and 7 stocks seeing inflows exceeding 10 million yuan, led by Aoyang Health with a net inflow of 94.61 million yuan [2][3] - Aoyang Health, Nengte Technology, and Shuiyang Shares had the highest net inflow ratios, with 42.28%, 6.86%, and 6.82% respectively [3][4] Group 2 - The top stocks in the hair medical concept sector based on net inflow include Aoyang Health, Shuiyang Shares, and Langzi Shares, with respective net inflows of 94.61 million yuan, 53.93 million yuan, and 24.89 million yuan [2][3] - The trading performance of Aoyang Health showed a daily increase of 10.08% with a turnover rate of 7.13%, while other notable performers included Shuiyang Shares and Langzi Shares with increases of 4.22% and 3.10% respectively [3][4] - The overall market sentiment in the hair medical sector appears positive, as indicated by the significant inflows and stock performance [1][2]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][59] Core Viewpoints - The report emphasizes the potential of the FIC molecule CKBA in the market, particularly recommending Tai En Kang [3][4] - The pharmaceutical index increased by 1.13% from June 2 to June 6, outperforming the CSI 300 index by 0.25% [5][30] - The report suggests focusing on innovative drugs as a clear industry trend, with specific recommendations for various companies [5][30] - The report highlights the ongoing clinical trials and potential market for CKBA, particularly in treating vitiligo and other autoimmune diseases [5][24][29] Summary by Sections Industry Performance - The pharmaceutical index saw a weekly increase of 1.13%, with 334 stocks rising and 144 falling [5][30] - Notable gainers included Yiming Pharmaceutical (+33.09%) and Wanbangde (+32.59%) [30][31] Recommended Stocks - The report recommends focusing on stocks such as Xinlitai, Huana Pharmaceutical, Rejing Bio, Sanofi Pharmaceutical, and Kunming Pharmaceutical [5][51] - For June, the suggested stocks include Xinlitai, Kelun Pharmaceutical, China Biopharmaceutical, and others [6][51] Clinical Development and Market Potential - CKBA, developed from the natural product AKBA, shows promise in treating vitiligo and other autoimmune diseases [5][24][29] - The clinical trials for CKBA ointment are progressing well, with results expected in July 2025 [29] Industry Outlook - The report anticipates a positive outlook for the pharmaceutical sector in 2025, driven by innovation, international expansion, and an aging population [48] - Key areas of focus include innovative drugs, overseas markets, domestic replacements, and high-barrier industries [48][49]